Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan · Delayed Price · Currency is TWD

90.40

+0.30 (0.33%)

Aug 7, 2026, 10:23 AM CST

-29.65% (1Y)

Market Cap	15.09B -30.4%
Revenue (ttm)	31.42M -27.9%
Net Income	-356.04M
EPS	-2.14
Shares Out	167.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	90.70
Previous Close	90.10
Day's Range	90.20 - 92.40
52-Week Range	85.80 - 329.50
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors. In addition, the compa... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 36

Stock Exchange Taipei Exchange

Ticker Symbol 6535

Full Company Profile

Financial Performance

In 2025, Lumosa Therapeutics's revenue was 35.83 million, a decrease of -8.49% compared to the previous year's 39.15 million. Losses were -340.54 million, -19.83% less than in 2024.

Financial Statements